SPRING-2 study (96-week data)

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naïve adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial

Raffi F, Jaeger H, Quiros-Roldan E, et al, on behalf of the extended SPRING-2 Study Group

Lancet Infect Dis 2013; 13: 927–935.

Read the full publication

You will need to register to view the full publication.

Sign me up for an account

UK/DTGP/0037/16q Date of Prep March 2017